IP Library Granted Patent US 8,197,812
Granted Patent B2
US 8,197,812 · App. 13/089,145 · Granted Jun 12, 2012

IL-1-like cytokine antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,197,812
App. No.
13/089,145
Granted
Jun 12, 2012
Kind
B2
Abstract

Nucleic acids encoding mammalian, e.g., primate, IL-1ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

Claims (29)

1. An isolated or purified antibody, or antigen binding fragment thereof, that specifically binds to a polypeptide having 95% sequence identity with the amino acid sequence of SEQ ID NO: 2.

2. The isolated or purified antibody, or antigen binding fragment thereof, of claim 1 comprising a monoclonal antibody.

3. The isolated or purified antibody, or antigen binding fragment thereof, of claim 1 comprising a humanized antibody.

4. The isolated or purified antibody, or antigen binding fragment thereof, of claim 1 comprising a human antibody.

5. The isolated or purified antibody, or antigen binding fragment thereof, of claim 1 comprising an Fv, Fab, or F(ab′) 2 fragment of an antibody.

6. The isolated or purified antibody, or antigen binding fragment thereof, of claim 1 further comprising a detectable label.

7. A composition comprising the isolated or purified antibody, or antigen binding fragment thereof, of claim 1 and a carrier, wherein the carrier comprises water, saline or buffer.

8. A composition comprising the isolated or purified antibody, or antigen binding fragment thereof, of claim 1 and a carrier, wherein the composition is formulated for oral, rectal, nasal, topical, or parenteral administration.

9. A method of making the isolated or purified antibody, or antigen binding fragment thereof, of claim 1 , comprising:

a) immunizing an animal with an immunogenic amount of the polypeptide of SEQ ID NO: 2; and

b) isolating an antibody that binds to the polypeptide of SEQ ID NO: 2 from said animal after immunization.

10. A method of producing an antigen:antibody complex, comprising:

a) contacting a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 with the antibody of claim 1 ; and

b) allowing the complex to form.

11. An isolated or purified antibody, or antigen binding fragment thereof, raised against a polypeptide having 95% sequence identity with the amino acid sequence of SEQ ID NO: 2.

12. The isolated or purified antibody, or antigen binding fragment thereof, of claim 11 comprising a monoclonal antibody.

13. The isolated or purified antibody, or antigen binding fragment thereof, of claim 11 comprising a humanized antibody.

14. The isolated or purified antibody, or antigen binding fragment thereof, of claim 11 comprising a human antibody.

15. The isolated or purified antibody, or antigen binding fragment thereof, of claim 11 comprising an Fv, Fab, or F(ab′) 2 fragment of an antibody.

16. The isolated or purified antibody, or antigen binding fragment thereof, of claim 11 further comprising a detectable label.

17. A composition comprising the isolated or purified antibody, or antigen binding fragment thereof, of claim 11 and a carrier, wherein the carrier comprises water, saline or buffer.

18. A composition comprising the isolated or purified antibody, or antigen binding fragment thereof, of claim 11 and a carrier, wherein the composition is formulated for oral, rectal, nasal, topical, or parenteral administration.

19. A method of making the isolated or purified antibody, or antigen binding fragment thereof, of claim 11 , comprising:

a) immunizing an animal with an immunogenic amount of the polypeptide of SEQ

ID NO: 2; and

b) isolating an antibody that binds to the polypeptide of SEQ ID NO: 2 from said animal after immunization.

20. A method of producing an antigen:antibody complex, comprising:

a) contacting a polypeptide comprising the amino acid sequence of SEQ ID NO: 2 with the antibody of claim 11 ; and

b) allowing the complex to form.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →